Novo Puts $4.6B on the Line to Expand Valo Deal, Maintain Cardiometabolic Leadership

The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with partnerships with Photys Therapeutics, Ascendis Pharma and two Flagship-backed start-ups.

Scroll to Top